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Dear Sir, 
Recently the most widely used treatment in the UK for canine hypoadrenocorticism (Addison’s 
disease) (fludrocortisone acetate; Florinef) has been taken off the market to the consternation of 
many owners who have come to rely on this drug for their pets. A similar though not identical 
generic form of fludrocortisone is available but it is about 6 to 7 times more expensive.  
Fortunately a drug, which is new to the UK but has been widely used in other countries, called 
desoxycortone pivalate (DOCP) is now available and is authorised for the treatment of canine 
hypoadrenocorticism (Zycortal; Dechra Ltd). However there are no established guidelines for 
changing dogs from fludrocortisone to Zycortal. We have already successfully transferred several 
dogs on to DOCP as part of a clinical trial and we would like to suggest a protocol to your readers in 
cases where the owner’s supply of fludrocortisone is about to be exhausted. 
Day 1: Inject Zycortal at 2.2 mg/kg by subcutaneous injection once every 25 days and give the dog’s 
usual dose of Florinef 
Day 2: Give the dog one half of the usual dose of Florinef. Start glucocorticoid (prednisolone) 
supplementation at 0.2 – 0.4 mg/kg by mouth once daily (or if currently on a higher dose of 
prednisolone then maintain that dose). 
Day 3: Give the dog one quarter of the usual dose of Florinef 
Day 4: No further Florinef 
If colleagues do not have sufficient fludrocortisone to perform this tapering dose then please note 
that in the original clinical trial dogs received their last fludrocortisone dose on the same day as their 
first Zycortal dose without ill effects. It is important to monitor sodium and potassium 
concentrations and adjust the dose according to the information available with the product.  
It is vital that, when starting Zycortal, prednisolone or other glucocorticoid supplement is started at 
the same time. In the long term, it may be possible to reduce the prednisolone dose, however this 
will still need to be given every day (do not attempt every other day treatment). In the, as yet 
unpublished, clinical registration trial the mean prednisolone dose at the start of the trial was 0.39 
mg/kg by mouth once daily, and the mean dose at the end of the trial was 0.13 mg/kg by mouth 
once daily. The prednisolone dose should be increased in times of metabolic stress such as surgery 
or illness by a factor of 2 to 4 times the dose (this is an empirical figure and should be adjusted 
according to the patient’s clinical signs). 
We are currently conducting a clinical trial under an Animal Test Certificate issued by the Veterinary 
Medicines Directorate examining the efficacy of fludrocortisone and Zycortal and we have stocks of 
(free) fludrocortisone and Zycortal for the dogs on this trial. We would welcome the referral of 
suitable cases from nearby practices to allow us to complete this trial.  
We hope that this advice is timely and helpful and reduces the number of calls to our and other 
hospitals.  
Yours sincerely 
Ian Ramsey, Emma Roberts, Susanna Spence 
University of Glasgow Small Animal Hospital 
464 Bearsden Road 
Bearsden  
Glasgow 
G61 1QH 
 
